^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

CYP17A1 inhibitor

8d
PARP Inhibitors Combined with Abiraterone Overcome Resistance in Metastatic Castration-Resistant Prostate Cancer Independently of Androgen Receptor. (PubMed, Cancers (Basel))
Overall, the results indicate that maintaining Abiraterone treatment in combination with PARPis after resistance develops provides superior therapeutic efficacy compared to PARP inhibition alone, offering a promising strategy for managing Abiraterone-resistant prostate cancer. Combining Abiraterone with PARPis enhances therapeutic efficacy and overcomes the acquired insensitivity in mCRPC with BRCA1/2 or HRR mutations. These results support continued use of PARPis with Abiraterone to improve clinical outcomes.
Journal • BRCA Biomarker • PARP Biomarker • IO biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • AR (Androgen receptor) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
|
BRCA2 mutation • BRCA1 mutation • BRCA wild-type
|
Lynparza (olaparib) • Zejula (niraparib) • abiraterone acetate
10d
Exercise training alters circadian clock dynamics in cancer-bearing male mice. (PubMed, Physiol Rep)
Scheduled exercise at ZT2 significantly increased the amplitude of Per2, Per3, and Rev-Erbα expression rhythms in tumor tissue...TNF-α acrophase was shifted in the ZT2 group, indicating a temporal immunomodulatory effect. Consistently performing exercise at the same time of day enhances tumor circadian clock genes rhythmicity, supporting chrono-exercise as a potential non-pharmacological adjuvant in cancer treatment.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • PER2 (Period Circadian Regulator 2) • PER1 (Period Circadian Clock 1) • PER3 (Period Circadian Regulator 3) • NR1D1 (Nuclear Receptor Subfamily 1 Group D Member 1)
|
Akeega (abiraterone/niraparib)
12d
Hot-yet-suppressed under PD-1 blockade: an RMP-NRF2-PD-L1 axis associated with a reduced proportional response in hepatocellular carcinoma. (PubMed, Front Immunol)
This suggests a limited response amplitude within the RMP/NRF2-high context...This dynamic accounts for the relatively lower inhibition observed in the overexpression context. The combined RMP/NRF2/PD-L1 signature proposes a mechanistically informed biomarker framework and suggests the potential for rational therapeutic combinations that pair PD-1 blockade with modulation of the redox pathway in HCC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule)
|
PD-L1 expression
|
Akeega (abiraterone/niraparib)
15d
Mitochondrial bioenergetics-SASP crosstalk determines senolytic efficacy in therapy-induced senescence. (PubMed, Cell Death Discov)
Inflachromene, an inhibitor of the chromatin remodelers HMGB1/2, decoupled mitochondrial bioenergetics from senolytic susceptibility, yielding SASP-null/miR146a-negative senescent cancer cells that were completely resistant to ABT-263/navitoclax and A1331852 despite extensive mitochondrial reprogramming. Thus, the senolytic response is governed by a layered circuit in which mitochondrial bioenergetic heritage establishes the senolytic ceiling, TIS-acquired bioenergetic flexibility fine-tunes the amplitude of the senolytic response, and establishing a mitochondria-inflammatory SASP crosstalk is required for BH3-mediated senolysis. These results support using functional readouts that integrate mitochondrial metabolic flexibility and inflammatory SASP to predict and potentially enhance senolytic efficacy in TIS cancer cells.
Journal
|
BCL2L1 (BCL2-like 1) • HMGB1 (High Mobility Group Box 1)
|
navitoclax (ABT 263) • A-1331852 • Akeega (abiraterone/niraparib)
17d
A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer (clinicaltrials.gov)
P1, N=12, Recruiting, Astellas Pharma Global Development, Inc. | Not yet recruiting --> Recruiting
Enrollment open
|
prednisone • abiraterone decanoate (ASP5541)
17d
New P1/2 trial
|
abiraterone acetate • prednisone • abiraterone decanoate (ASP5541)
17d
PET/CT Characterization of Treatment Resistance (clinicaltrials.gov)
P=N/A, N=25, Recruiting, University of Wisconsin, Madison | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Mar 2026 --> Sep 2026
Trial completion date • Trial primary completion date
|
abiraterone acetate
17d
Anti-apoptotic BCL-2 binds to all three IP3R isoforms, thereby limiting the Ca2+-flux properties of IP3R homo-tetramers. (PubMed, Open Biol)
BCL-2 overexpression reduced the number of Ca²+ puffs across all IP3R isoforms without affecting the amplitude or duration of individual puffs. Thus, BCL-2 acts as a universal inhibitor of all three IP3R isoforms, highlighting its critical role in fine-tuning intracellular Ca2+ dynamics to promote cell survival and its potential as a therapeutic target in cancer via its role in Ca2+ signalling.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
Akeega (abiraterone/niraparib)
19d
Single versus repeated intravenous oncolytic reovirus infusions: Implications for immune modulation and rationalised scheduling of therapy in hepatocellular carcinoma. (PubMed, Int J Cancer)
Repeated doses on consecutive days do not improve the amplitude of the immune response following virus infusion. Furthermore, without improving therapeutic efficacy, repeated viral dosing leads to an unwanted influx of activated T-cells into background liver, alongside elevated liver enzymes associated with aberrant liver function. A single dose of reovirus is as effective as multiple doses when combined with anti-PD-L1 therapy in limiting tumour growth and extending survival in vivo, whilst simultaneously avoiding undesirable toxicities in background liver, in the context of HCC.
Journal
|
CD8 (cluster of differentiation 8)
|
Akeega (abiraterone/niraparib)
19d
Investigating the correlation of glucose-regulated protein 78 with sperm motility and kinematic parameters insights into male fertility. (PubMed, J Anim Sci Technol)
However, GRP78 expression did not exhibit a significant correlation with progressive sperm motility, average path velocity, curvilinear velocity, straight-line velocity, and amplitude of lateral head displacement. These results provide novel insights into the correlation between GRP78 and sperm motility, as well as its potential implications for male fertility.
Journal
|
HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5)
|
Akeega (abiraterone/niraparib)
20d
The Regenerative Effects of Intracordal Injection of Basic Fibroblast Growth Factor for Vocal Fold Scar After Burn or Radiotherapy: A Preliminary Report. (PubMed, J Voice)
This preliminary report suggests that intracordal bFGF injection may be effective for some cases even with severe vocal fold scar caused by radiotherapy, while the effects for burn-related scar remain unclear. Further investigation in a larger cohort is warranted to explore more information about the therapy.
Journal
|
FGF (Fibroblast Growth Factor)
|
Akeega (abiraterone/niraparib)
20d
Multimodal brain-gut-sleep phenotypes predict delirium, long-term cognitive decline, and survival after colorectal cancer surgery. (PubMed, Psychoneuroendocrinology)
Multimodal brain-gut-sleep phenotypes strongly predict delirium, long-term cognition, and survival after colorectal cancer surgery. These findings support a systems-based model in which perioperative resilience reflects coordinated regulation of circadian, microbial, autonomic, inflammatory, and psychological pathways.
Journal
|
IL6 (Interleukin 6)
|
Akeega (abiraterone/niraparib)